Thromboembolism After Intramedullary Nailing for Metastatic Bone Lesions. by Shallop, Brandon et al.
Thomas Jefferson University
Jefferson Digital Commons
Rothman Institute Rothman Institute
9-16-2015
Thromboembolism After Intramedullary Nailing
for Metastatic Bone Lesions.
Brandon Shallop
Jefferson Medical College, brandon.shallop@jefferson.edu
Alexandria Starks
Jefferson Medical College, alexandriaostarks@gmail.com
Simon Greenbaum
Albert Einstein Medical College
David S Geller
Montefiore Medical Center
Alan Lee
Brigham and Women's Hospital
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/rothman_institute
Part of the Orthopedics Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Rothman Institute by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Shallop, Brandon; Starks, Alexandria; Greenbaum, Simon; Geller, David S; Lee, Alan; Ready, John;
Merli, Geno J; Maltenfort, PhD, Mitchell; and Abraham, John A, "Thromboembolism After
Intramedullary Nailing for Metastatic Bone Lesions." (2015). Rothman Institute. Paper 67.
http://jdc.jefferson.edu/rothman_institute/67
Authors
Brandon Shallop; Alexandria Starks; Simon Greenbaum; David S Geller; Alan Lee; John Ready; Geno J
Merli; Mitchell Maltenfort, PhD; and John A Abraham
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/rothman_institute/67
Thromboembolism After Intramedullary
Nailing for Metastatic Bone Lesions
Brandon Shallop, MD, Alexandria Starks, MD, Simon Greenbaum, MD, David S. Geller, MD, Alan Lee, MD,
John Ready, MD, Geno Merli, MD, Mitchell Maltenfort, PhD, and John A. Abraham, MD
Investigation performed at Thomas Jefferson University, Philadelphia, Pennsylvania
Background: The risk of venous thromboembolism (VTE) in patients undergoing intramedullary nailing for skeletal
metastatic disease is currently undeﬁned. The purpose of our study was to determine the risk of thromboembolic events,
to deﬁne the risk factors for VTE, and to deﬁne the rate of wound complications in this population.
Methods: A retrospective review of surgical databases at three National Cancer Institute (NCI)-designated cancer cen-
ters identiﬁed 287 patients with a total of 336 impending or pathologic long-bone fractures that were stabilized with
intramedullary nailing between February 2001 and April 2013. Statistical analysis was performed utilizing multivariable
logistic regression and Fisher exact tests.
Results: The overall rate of VTE was twenty-four (7.1%) of the 336; thirteen (3.9%) were pulmonary embolism (PE), and
eleven (3.3%), deep venous thrombosis (DVT). In two patients, adequate anticoagulation data were not available. We
found no signiﬁcant relationship between the type of anticoagulant used and VTE. There was a signiﬁcant positive cor-
relation found between lung-cancer histology and the development of VTE (p < 0.001) or PE (p < 0.001). The absence of
radiation therapy approached signiﬁcance (p = 0.06) with respect to decreased overall VTE risk. Wound complications
were documented for 11 (3.3%) of the operations.
Conclusions: There is a high rate of VTE among those with skeletal metastatic disease who undergo intramedullary
nailing, even while receiving postoperative thromboembolic prophylaxis. Current anticoagulation protocols may be inad-
equate. Wound-complication risk with anticoagulant use in this population is low and should not be a deterrent to ade-
quate anticoagulant use for this population.
Level of Evidence: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
I
mpending and pathologic fractures of long bones in patients
with metastatic skeletal disease are generally treated with
intramedullary nailing. The combination of neoplastic dis-
ease, loss of mechanical stability, vessel damage, and immobility
would theoretically put these patients at substantial risk for
the development of venous thromboembolism (VTE), which
includes both deep venous thrombosis (DVT) and pulmonary em-
bolism (PE).
There are many known risk factors for the development
of VTE1,2. Virchow’s original description of this problem pro-
posed that VTE occurs as the result of a triad of factors: al-
terations in blood ﬂow, vascular endothelial injury, and a
hypercoagulable state3. The relatively high VTE risk of ortho-
paedic procedures4 is related to intraoperative and postopera-
tive factors. Estimated rates of inpatient DVT and PE among
patients receiving prophylaxis following hip or knee arthro-
plasty are approximately 0.5% to 1%5. The risk of VTE is also
increased in long-bone fractures6-12. Aggressive anticoagulation
postoperatively, however, must be balanced with the risk of
severe wound or bleeding complications13,14.
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work, with an entity in the biomedical arena that could be perceived to inﬂuence or have the potential to inﬂuence what is written in this work. No author has
had any other relationships, or has engaged in any other activities, that could be perceived to inﬂuence or have the potential to inﬂuence what is written in this
work. The complete Disclosures of Potential Conﬂicts of Interest submitted by authors are always provided with the online version of the article.
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The mechanisms for cancer-related hypercoagulability in-
clude cancer procoagulant, vascular compression or tumor in-
vasion, prothrombotic chemotherapy, and radiation therapy15,16.
VTE was found to occur in up to 11% of patients with cancer17,18,
and cancer patients undergoing orthopaedic surgery are pre-
sumably at very high risk19,20. Indeed, a recent study demonstrated
a mildly increased risk of VTE in cancer patients undergoing
routine joint arthroplasty when cancer was not present at the site
of the operation (odds ratio [OR] = 1.2 to 1.6); the risk sub-
stantially increased when the arthroplasty was performed for an
oncologic indication (OR = 6.6)21. The risk factors for VTE in
patients with malignancy have been described in a number of
large, population-based, case-control studies22-28, but the risk in
patients undergoing intramedullary nailing for prophylactic ﬁx-
ation related to skeletal metastases is unknown.
The purpose of the current study was to determine the risk
of thromboembolic events in patients with metastatic long-bone
cancer undergoing intramedullary nailing for skeletal metastatic
disease, to deﬁne the risk factors for developing VTE in this group,
and to deﬁne the rate of wound complications in this population.
Materials and Methods
Data Collection
After institutional review board approval, a retrospective review of surgicaldatabases at three National Cancer Institute (NCI)-designated cancer cen-
ters identiﬁed 287 patients with a total of 336 impending or pathologic long-bone
fractures that were stabilized with intramedullary nailing between February 2001
and April 2013. In all cases, the treating orthopaedic oncologist determined the
postoperative anticoagulation protocol. These three institutions were chosen
because of the variation in postoperative anticoagulation regimens, while main-
taining identical surgical technique. Postoperatively, patients were generally al-
lowed to bear full weight on the operatively treated limb immediately after surgery.
Data and Statistical Analysis
Adjuvant therapies recorded included any postoperative radiation speciﬁcally to the
affected limb and any postoperative chemotherapy. Speciﬁc details of chemother-
apeutic agents used were not obtained in all cases. Rates of documented VTE,
divided into PE and DVT, and any postoperative anticoagulation details were re-
corded. Routine lower-extremity screening ultrasounds were not obtained in any of
the centers studied, so it is likely that all DVTs identiﬁed were symptomatic because
all patients with DVT did have ultrasound documentation. With the exception of
one patient with renal cell carcinoma, who was diagnosed with use of a ventilation/
perfusion (V/Q) scan, all patients with PE had documentation by a chest computed
tomography (CT) scan. Wound complications, deﬁned as requiring either reoper-
ation or othermodiﬁcation of treatment (such as the initiation of antibiotic therapy),
were recorded. Statistical analysis was performed by a statistician utilizing Fisher
exact tests and multivariable logistic regression analysis. ORs and 95% conﬁdence
intervals (CIs) were calculated. A p value of <0.05 was considered signiﬁcant.
Source of Funding
No external funding was received for this study.
Results
Patient Demographics
Patient demographics and clinical and disease-speciﬁc charac-teristics are shown in Table I. Of the 287 patients, the median
age was 60.5 years (range, twenty-eight to ninety-four years).
One hundred and fourteen (39.7%) of the patients were male,
and 173 (60.3%) were female. Of the 336 operations, 264
TABLE I Patient Demographics and Clinical and Disease-Speciﬁc
Characteristics
Total patients (no.) 287
Total operations (no.) 336
Age* (yr) 60.5 (28-94)
Sex (no. [%])
Male 114 (39.7)
Female 173 (60.3)
Bone (no. [%])
Femur 264 (78.6)
Humerus 62 (18.4)
Tibia 10 (3.0)
Lesion (no. [%])
Impending fracture 301 (89.6)
Pathologic fracture 35 (10.4)
Histology (no. [%])
Lung 87 (25.9)
Breast 81 (24.1)
Multiple myeloma 50 (14.9)
Renal cell carcinoma 25 (7.4)
Metastatic sarcoma 13 (3.9)
Melanoma 10 (3.0)
Esophageal 9 (2.7)
Prostate 7 (2.1)
Hepatocellular
carcinoma/
cholangiocarcinoma
7 (2.1)
Gynecological
cancer (ovarian,
cervical, endometrial,
uterine)
7 (2.1)
Thyroid 6 (1.8)
Lymphoma 4 (1.2)
Colon/rectal 4 (1.2)
Bladder 3 (0.9)
Leukemia 3 (0.9)
Pancreatic 2 (0.6)
Other† 10 (3.0)
Unknown primary 8 (2.4)
Adjuvant therapy (no. [%])
Radiation
Yes 206 (61.3)
No 124 (36.9)
Unknown 6 (1.8)
Chemotherapy
Yes 179 (53.3)
No 107 (31.8)
Unknown 50 (14.9)
*The values are presented as the median with the range in pa-
rentheses. †Other = stromal, parotid, neuroendocrine, squamous,
gastrointestinal, adenoid, brain, and salivary.
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(78.6%) involved the femur; 62 (18.4%), the humerus; and
10 (3.0%), the tibia. Eighteen major cancer diagnostic categories
were identiﬁed (Table I).
Adjuvant Therapies
Any postoperative radiation therapy delivered to the affected
limb commencing within a two-week time frame of surgery
was recorded. Dosages ranged from 20 to 40 Gy. Details of
the radiation ﬁeld and non-VTE radiation-associated complica-
tions were not recorded. Because of the large variety of primary
oncologic diseases and the corresponding large number of
medical oncology physicians treating the patients in the study
population, detailed records regarding the speciﬁcs of chemo-
therapy used could not be obtained in all cases. The distribution
of adjuvant therapies is shown in Table I.
Anticoagulant Data
Low-molecular-weight heparin was the most frequently used
anticoagulant and was documented for 203 (60.4%) of the 336
operations (enoxaparin, in 150 [44.6%]; and dalteparin, in
ﬁfty-three [15.8%]). With the exception of patients who re-
quired a treatment dose, or who had a history of thromboem-
bolic disease, the general dosages used were thromboembolic
prophylactic doses: for enoxaparin, 40 mg daily, and for dalte-
parin, 5000 IU daily. Warfarin (dosed to maintain an interna-
tional normalized ratio [INR] goal of 2.0 to 2.5) was used for
ﬁfty-six (16.7%) of the operations; subcutaneous heparin
(5000 units every twelve hours), eighteen (5.4%); aspirin (325mg
daily), seventeen (5.1%); and fondaparinux (10 mg daily),
three (0.9%). In general, all centers utilized a protocol of two
weeks of chemical anticoagulation postoperatively, but the
exact duration of anticoagulation could not be conﬁrmed for
all cases. Neither patient compliance in the use of injectable
anticoagulants (low-molecular-weight heparin, fondaparinux,
and subcutaneous heparin) nor maintenance of the INR within
the target range for the duration of warfarin administration
could be veriﬁed for every case. For thirty-seven (11.0%) of the
TABLE III Demographic, Clinical, and Disease-Speciﬁc
Characteristics of VTE Cases
VTE events (no.)
Total 24
DVT 11
PE 13
No. (%) of patients
Total 19 (6.6)
Male 4 (21.1)
Female 15 (78.9)
Age* (yr) 59 (43-81)
No. (%) of operations 21 (6.3)
Bone (no. [%])
Femur 19 (90.5)
Humerus 2 (9.5)
Lesion (no. [%])
Impending fracture 20 (95.2)
Pathologic fracture 1 (4.8)
Histology (no. [%])
Lung 14 (66.7)
Breast 4 (19.0)
Multiple myeloma 1 (4.8)
Renal cell carcinoma 1 (4.8)
Melanoma 1 (4.8)
Adjuvant therapy (no. [%])
Radiation
Yes 9 (42.9)
No 12 (57.1)
Chemotherapy
Yes 6 (28.6)
No 11 (52.4)
Unknown 4 (19.0)
Anticoagulant (no. [%])
Low-molecular-weight heparin 16 (76.2)
Warfarin 3 (14.3)
Subcutaneous heparin 2 (9.5)
*The values are presented as the median, with the range in
parentheses.
TABLE II Anticoagulation, VTE, and Wound-Complication Data
No. (%)
Anticoagulant
Low-molecular-weight heparin 203 (60.4)
Enoxaparin 150 (44.6)
Dalteparin 53 (15.8)
Coumadin (warfarin) 56 (16.7)
Subcutaneous heparin 18 (5.4)
Aspirin 17 (5.1)
Arixtra (fondaparinux) 3 (0.9)
None 37 (11.0)
Unknown 2 (0.6)
VTE 24 (7.1)
DVT 11 (3.3)
PE 13 (3.9)
Infections and other wound
complications
11 (3.3)
Hematoma 3 (0.9)
Infection requiring irrigation and
debridement
2 (0.6)
Superﬁcial cellulitis 2 (0.6)
Wound warmth and erythema 2 (0.6)
Wound breakdown 1 (0.3)
Septic shock 1 (0.3)
Both VTE and wound complication 0 (0.0)
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operations, no form of chemical anticoagulant was given,
and for two (0.6%), the anticoagulant could not be veriﬁed
(Table II).
VTE Data
There were twenty-four documented VTE events: thirteen PE
(3.9% of the operations) and eleven DVT (3.3%) (Table III).
TABLE IV Patient Data for VTE Events
Sex Age (yr) Histology Bone
Fracture
Type Radiation Chemotherapy Anticoagulant DVT PE
Postoperative
Day
F 57 Multiple
myeloma
Humerus Pathologic Yes Yes Enoxaparin Yes No 0
F 67 Lung Femur Impending Yes Unknown Dalteparin Yes Yes 21
F 63 Breast Femur Impending Yes Unknown Dalteparin Yes Yes 2
M 59 Lung Femur Impending Yes Unknown Dalteparin No Yes 1
F 67 Lung Femur Impending No Unknown Dalteparin Yes Yes 15
M 60 Lung Femur Impending No No Warfarin Yes Yes 7
F 70 Renal cell
carcinoma
Femur Impending Yes Yes Enoxaparin No Yes 48
F 61 Lung Humerus
and femur*
Impending No No Enoxaparin No Yes 15
F 52 Lung Femur and
femur*
Impending No No Heparin No Yes 0
F 64 Lung Femur Impending No No Enoxaparin No Yes 4
F 57 Lung Femur Impending No No Dalteparin No Yes 55
M 55 Lung Femur Impending No No Enoxaparin No Yes 10
F 57 Lung Femur Impending Yes Yes Dalteparin No Yes 3
F 43 Breast Femur Impending No Yes Enoxaparin Yes Yes 53
F 48 Breast Femur Impending Yes Yes Enoxaparin Yes No 2
M 70 Lung Femur Impending No No Warfarin Yes No 7
F 59 Breast Femur Impending No No Warfarin Yes No 7
F 48 Lung Femur Impending Yes Yes Enoxaparin Yes No 31
F 81 Melanoma Femur Impending Yes No Enoxaparin Yes No 38
*Fixation of two impending fractures.
Fig. 1
The number of VTE events according to time of occurrence.
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The twenty-four events occurred in nineteen (6.6%) of the
patients (twenty-one [6.3%] of the nailing procedures). The
patients (four [21.1%] male and ﬁfteen [78.9%] female) had a
median age of ﬁfty-nine years (range, forty-three to eighty-one
years). Lung cancer was themost common oncologic diagnosis.
In nine (42.9%) of the twenty-one cases, adjuvant radiation
was received, and in six (28.6%), adjuvant chemotherapy. Low-
molecular-weight heparin was the most frequently used anti-
coagulant in the subset of patients who developed VTE. Table
IV shows data recorded for each of the nineteen patients who
developed VTE. The highest VTE incidence occurred during
the ﬁrst ﬁfteen days following surgery, with the last event
documented at ﬁfty-ﬁve days after surgery (Fig. 1).
Infections and Other Wound Complications
Infections and other wound complications were documented
for eleven (3.3%) of the operations (Table II). None of the
patients with wound complications had VTEs. There were three
hematomas (0.9% of the operations) requiring alteration in
anticoagulation therapy or operative release, two (0.6%) major
or deep infections requiring irrigation and debridement, two
cases (0.6%) of culture-positive superﬁcial cellulitis requiring
TABLE V Patient Data for Wound Complications and Infections
Sex Age (yr) Histology Bone
Fracture
Type Radiation Chemotherapy Anticoagulant VTE Complication
F 59 Multiple
myeloma
Femur Impending No Yes Warfarin No Thigh hematoma
F 67 Melanoma Femur and
femur*
Impending No Yes Enoxaparin No Septic shock
(died)
F 75 Hepatocellular
carcinoma
Femur Impending No Unknown None No Hematoma
F 58 Breast Femur Impending Yes Yes Enoxaparin No Wound erythema
and warmth at
incision
M 73 Renal cell
carcinoma
Tibia Impending No Yes Aspirin No Wound erythema
and warmth at
incision
M 72 Renal cell
carcinoma
Tibia Impending Yes Yes Warfarin No Infected nonunion
requiring nail
removal, staged
irrigation and
debridement
F 68 Breast Femur Impending Yes Yes Enoxaparin No Wound
breakdown
F 53 Breast Femur Impending Yes Yes Warfarin No Wound infection
requiring irrigation
and debridement
M 34 Colon Femur Impending No Yes Warfarin No Hematoma
F 72 Ovarian Tibia Impending No Yes Enoxaparin No Superﬁcial
cellulitis
M 55 Lung Femur Impending Yes Yes Warfarin No Superﬁcial
cellulitis
*Fixation of two impending fractures.
TABLE VI Multivariable Logistic Regression Analysis of VTE Risk
Variable
Odds
Ratio 95% CI P Value
Sex (male) 0.26 0.07-1.07 0.062
Age (per yr) 0.96 0.90-1.01 0.129
Histology
Lung vs. others 7.49 1.56-36.07 0.012
Extremity
Upper vs. lower 0.49 0.08-2.87 0.427
Location
Proximal vs. distal 0.56 0.17-1.83 0.336
Pathologic fracture 1.64 0.16-16.84 0.679
Anticoagulant
LMWH vs. others* 1.73 0.53-5.62 0.362
No radiation vs. radiation 0.35 0.10-1.20 0.096
Chemotherapy 0.43 0.11-1.63 0.215
*LMWH = low-molecular-weight heparin.
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antibiotic treatment, two cases (0.6%) of wound warmth and
erythema (suspected to be cellulitis but without documented
culture data) requiring antibiotic treatment, one case (0.3%) of
wound breakdown requiring packing and dressing changes,
and one case (0.3%) of septic shock in the setting of suspected
wound infection with resultant death. There was no correlation
between a speciﬁc anticoagulant and the rate of a wound com-
plication (Table V).
Statistical Analysis
Univariable Analysis
Fisher exact tests were used to determine whether a signiﬁcant
relationship existed between the development of DVT or PE
and cancer histology, use of anticoagulation, or use of radiation
therapy. In the primary tumor analysis, we found a signiﬁcantly
increased risk of the development of PE in patients with lung-
cancer histology (OR = 13.2 [95% CI = 3.45 to 74.94]; p <
0.0001) and also a relationship between lung-cancer histology
and the development of VTE overall (OR = 6.7 [95% CI = 2.42
to 20.40]; p < 0.0001). However, we did not ﬁnd a clear rela-
tionship between the development of DVT and lung-cancer
histology (OR = 2.5 [95% CI = 0.59 to 10.13]; p = 0.16).
In the analysis of anticoagulant use, we did not identify a
signiﬁcant relationship between the use of any of the antico-
agulants studied and the development of DVT, PE, or VTE (p =
0.69, p = 0.27, and p = 0.32, respectively).
There was a signiﬁcant decrease in the risk of the devel-
opment of PE in patients who did not receive radiation therapy
(OR = 0.28 [95% CI = 0.7 to 0.94]; p = 0.026), but a relationship
between the use of radiation therapy and DVT could not be
shown (OR = 0.71 [95% CI = 0.18 to 3.00]; p = 0.75). We did
ﬁnd a slightly decreased risk, which approached signiﬁcance,
of the development of VTE overall in patients who did not
receive radiation therapy (OR = 0.43 [95% CI = 0.15 to 1.14];
p = 0.064).
Multivariable Analysis
Multivariable logistic regression analysis was then performed to
look at VTE risk overall as well as PE and DVTrisk speciﬁcally.
As demonstrated in the univariable analysis, we found a sig-
niﬁcantly increased risk of the development of VTE overall in
patients with lung-cancer histology (OR = 7.49 [95% CI =1.56
to 36.07]; p = 0.012). The relationship between the absence
of radiation therapy and the development of VTE approached
signiﬁcance (OR = 0.35 [95% CI = 0.10 to 1.20]; p = 0.096)
(Table VI).
With respect to the development of PE, we found a sig-
niﬁcantly increased risk in patients with lung-cancer histology
(OR = 24.35 [95% CI = 2.03 to 291.2]; p = 0.011) and a
decreased risk in patients who did not receive radiation therapy
(OR = 0.10 [95% CI = 0.01 to 0.73]; p = 0.023) (Table VII).
With respect to DVTrisk speciﬁcally (Table VIII), we found no
signiﬁcant correlation between the risk of the development of
DVT and any of the variables tested.
Discussion
Patients undergoing intramedullary nailing for skeletalmetastatic disease are at high risk for the development of a
thromboembolic event postoperatively. Our goal was to in-
vestigate the risk of VTE and the rate of wound complications
in this population, and our study included a series of 287
consecutive patients treated with intramedullary nailing for
336 metastatic long-bone lesions. We performed both univariable
analysis and, using all variables presumed to be relevant to VTE,
multivariable analysis.
TABLE VII Multivariable Logistic Regression Analysis of PE Risk
Variable
Odds
Ratio 95% CI P Value
Sex (male) 0.28 0.05-1.63 0.155
Age (per yr) 0.93 0.85-1.01 0.083
Histology
Lung vs. others 24.35 2.03-291.25 0.011
Extremity
Upper vs. lower 0.35 0.02-4.81 0.429
Location
Proximal vs. distal 0.47 0.10-2.35 0.361
Pathologic fracture 0.00 0.00-1060 0.900
Anticoagulant
LMWH vs. others* 2.05 0.42-10.10 0.377
No radiation vs. radiation 0.10 0.01-0.73 0.023
Chemotherapy 0.61 0.09-3.94 0.599
*LMWH = low-molecular-weight heparin.
TABLE VIII Multivariable Logistic Regression Analysis of
DVT Risk
Variable
Odds
Ratio 95% CI P Value
Sex (male) 0.78 0.12-5.21 0.797
Age (per yr) 0.98 0.92-1.05 0.545
Histology
Lung vs. others 1.10 0.15-8.11 0.927
Extremity
Upper vs. lower 0.51 0.05-5.38 0.573
Location
Proximal vs. distal 0.48 0.09-2.39 0.367
Pathologic fracture 1.63 0.14-19.24 0.696
Anticoagulant
LMWH vs. others* 1.07 0.23-4.96 0.929
No radiation vs. radiation 0.64 0.13-3.02 0.571
Chemotherapy 0.56 0.10-3.10 0.507
*LMWH = low-molecular-weight heparin.
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Demographic data demonstrated a median age of 60.5
years (Table I). As expected, the femur was the most common
site, followed by the humerus, and then the tibia. Although we
suspected there may be a difference in risk of VTE on the basis
of location—because lesions in the lower extremity have greater
impact on patient mobility—this was not our ﬁnding. The fact
that the location of the lesion did not confer additional risk for
VTE, even in the case of pathologic fracture, may suggest that the
effect of having skeletal metastatic disease alone outweighs the
VTE risk imparted by immobility due to the presence of, or
fracture through, a lesion.
The overall rate of thromboembolic events in this study
population was 7.1% (twenty-four of 336), with eleven of the
twenty-four being DVT, and thirteen of the twenty-four, PE.
Interestingly, the development of VTE was not signiﬁcantly re-
lated to the type of anticoagulant used. The study populationwas
treated with a variety of postoperative anticoagulants, including
low-molecular-weight heparin, Coumadin (warfarin), aspirin,
fondaparinux, and heparin, or in some cases, no chemical anti-
coagulation at all. Given the relatively low numbers of throm-
boembolic events seen in this study, it is possible that the study
was underpowered to detect a difference among these agents.
However, given the high number of risk factors in this patient
population, it is also possible that none of the current regimens of
postoperative thromboembolic prophylaxis substantially decrease
the risk of DVTor PE when compared with no anticoagulation. A
study designed to speciﬁcally answer this question is required.
Regarding the timing of VTE in this population after
surgery, we considered the ninety-day period after the operation
to be the “postoperative period” in which the incidence of VTE
was investigated. A New England Journal of Medicine study on
abdominal cancer surgery, in which patients were randomized
to placebo versus enoxaparin as a thromboembolic prophylactic
agent, demonstrated a signiﬁcant difference with respect to the
development of thromboembolic events for three months29. The
landmark “MillionWomen Study” found signiﬁcantly increased
risk of postoperative thromboembolism for twelve weeks in 1.3
million women with breast cancer undergoing surgical proce-
dures for the cancer30. On the basis of this literature, we elected to
include any VTE within a ninety-day period postoperatively as
a “postoperative” event. As demonstrated in Figure 1, although
half of the documented VTE events occurred within about two
weeks after surgery, there were continued events noted as far as
ﬁfty-ﬁve days after surgery. This suggests that if there were an
anticoagulant that could adequately prevent VTE, but it was used
only for two weeks, it would have prevented only about half of
the noted VTE events in this study. This potentially supports
a longer duration of treatment, which is consistent with the
ﬁndings of the Million Women Study30. Considering the high
risk associated with this population, we believe this is likely
warranted. Further investigation is needed to elucidate the pre-
cise ideal duration of anticoagulation postoperatively in this
population.
Although we did not ﬁnd a signiﬁcant relationship be-
tween sex and VTE, multivariable logistic regression analysis
showed a borderline signiﬁcant relationship (OR = 0.26 [95%
CI= 0.07 to 1.07]; p= 0.062) betweenmale sex and decreased risk
of VTE, and we observed that a high percentage (78.9%) of pa-
tients who developed VTE were female. There may be a rela-
tionship between female sex and development of VTE that we
could not demonstrate because the study was underpowered. In
studies of risk factors for VTE in the general (i.e., noncancer)
population, females in childbearing years have a higher risk of
DVT than do males, but this risk reverses after the age of ﬁfty,
when males are found to have a higher risk31. It is suspected that
hormonal factors present in females during childbearing years, or
other factors such as oral contraceptive use in the general pop-
ulation, may contribute to this increased risk. In the cancer
population, alteration of the hormonal milieu could theoretically
contribute to a sex-related risk. Although our study was not de-
signed to investigate these speciﬁc concepts, the observation is
interesting to note.
As expected, various primary histologies were seen in
our patient population. When compared with other histologies,
there was a signiﬁcantly higher risk of developing VTE in patients
with a primary tumor of the lung, which was demonstrated in
both univariable and multivariable analyses. This is similar to
other studies of thromboembolic events in patients with primary
cancers that have shown that lung cancer is the most common
primary cancer diagnosis at the time of a VTE event28,32. Possible
reasons for this increased risk for lung cancer patients include a
hypercoagulable state, substantial chemotherapy usage, circulat-
ing procoagulants, or other undescribed factors unique to lung
cancer patients.
Adjuvant therapies used included both chemotherapy and
radiation therapy. Although a signiﬁcant decrease in VTE risk in
patients who were not receiving radiation therapy could not be
demonstrated, this relationship did approach signiﬁcance in
both univariable (OR = 0.43 [95% CI = 0.15 to 1.14]; p = 0.064)
and multivariable analysis (OR = 0.35 [95% CI = 0.10 to 1.20];
p = 0.096). Patients who did not receive radiation therapy were
found to be at decreased risk for PE in both univariable and
multivariable analyses. A signiﬁcant relationship between the use
of radiation therapy and increased risk of DVT could not be
shown in this study. This is likely due to the study being un-
derpowered to detect these individual differences. Overall, these
ﬁndings are in agreement with those of other studies, which
suggest that radiation increases the risk of VTE33.
The overall rate of wound complications was 3.3%. Al-
though we did not ﬁnd a relationship between the anticoagu-
lant used and the development of wound complications, this
is a relatively rare complication, and the numbers for each type
of anticoagulant were low, so the study was very likely under-
powered to detect a difference. In arthroplasty procedures, there
is a well-documented increase in wound complications with
increasing levels of anticoagulation34. As the incisions and dis-
section required for intramedullary nailing are much more
limited than arthroplasty incisions, it is possible that the wound
complication risk is less dependent on the anticoagulant used
than it is in arthroplasty. In this study, only two patients
(0.6% of the operations) required a repeat operation for deep
wound infection, and only one of the patients required removal
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of the hardware. This again is considerably different from
ﬁndings for the arthroplasty population, in which a higher rate
of implant removal is seen secondary to wound complica-
tions35-37. The use of intramedullary nailing in the setting of
trauma also has been associated with a low risk of wound
complication or infection requiring removal of the implant38.
These results suggest, given the low risks of infection, wound
complications, and hardware removal, that at least from a
wound-risk standpoint, more aggressive anticoagulation could
potentially be tolerated. Further study with a much larger pop-
ulation would be needed to determine if wound complication
risk varies by anticoagulant.
Our study had several limitations. This was a retrospec-
tive study, and the limitations of this type of study design apply.
Although it involved, to our knowledge, the largest series of its
kind, the number of patients and thromboembolic events was
still relatively small, which introduces the possibility that the
study was underpowered to detect small differences and rare
complications. Only symptomatic VTE was included in the
study, which likely represents an underestimation of the true
VTE occurrence in this population. This is a highly complex
patient population, with multiple comorbidities and other
disease-related factors, which could have had a confounding
effect on our study.
On the basis of our results, several considerations are
warranted. First, it is likely that the optimal postoperative anti-
coagulation protocol for this population has yet to be deter-
mined, and a clinical trial would be useful in elucidating the
optimal postoperative management. Second, because the rate of
wound complications seen in this study and in other studies is
very low, and implant retention is the norm in the setting of
wound complication, more aggressive anticoagulation may not
introduce a notable patient morbidity speciﬁcally from the
standpoint of wound risk. Third, anticoagulation protocols may
need to be adjusted according to the patient’s particular primary
disease. Likewise, the optimal anticoagulation protocol should
take into account the use of postoperative radiation therapy. The
risk of thromboembolic events in the population of patients
undergoing intramedullary nailing for metastatic disease in-
volving long bones is clearly high, and the results presented here
suggest that the current approach to anticoagulation therapy
in this patient population is likely to be inadequate. n
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